AUPN531195A0 - Lipid extract having anti-inflamatory activity - Google Patents

Lipid extract having anti-inflamatory activity

Info

Publication number
AUPN531195A0
AUPN531195A0 AUPN5311A AUPN531195A AUPN531195A0 AU PN531195 A0 AUPN531195 A0 AU PN531195A0 AU PN5311 A AUPN5311 A AU PN5311A AU PN531195 A AUPN531195 A AU PN531195A AU PN531195 A0 AUPN531195 A0 AU PN531195A0
Authority
AU
Australia
Prior art keywords
pct
lipid extract
date
sec
inflamatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPN5311A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JW Broadbent Nominees Pty Ltd
Original Assignee
JW Broadbent Nominees Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JW Broadbent Nominees Pty Ltd filed Critical JW Broadbent Nominees Pty Ltd
Priority to AUPN5311A priority Critical patent/AUPN531195A0/en
Publication of AUPN531195A0 publication Critical patent/AUPN531195A0/en
Priority to PT96929129T priority patent/PT850068E/pt
Priority to JP51149997A priority patent/JP4101876B2/ja
Priority to DK96929129T priority patent/DK0850068T3/da
Priority to AU68656/96A priority patent/AU703368B2/en
Priority to ES96929129T priority patent/ES2241001T3/es
Priority to US09/029,957 priority patent/US6083536A/en
Priority to DE69634666T priority patent/DE69634666T2/de
Priority to PCT/AU1996/000564 priority patent/WO1997009992A1/en
Priority to EP96929129A priority patent/EP0850068B1/en
Priority to AT96929129T priority patent/ATE293984T1/de
Priority to CA002231803A priority patent/CA2231803C/en
Priority to ZA9607626A priority patent/ZA967626B/xx
Priority to US09/610,484 priority patent/US6346278B1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AUPN5311A 1995-09-11 1995-09-11 Lipid extract having anti-inflamatory activity Abandoned AUPN531195A0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
AUPN5311A AUPN531195A0 (en) 1995-09-11 1995-09-11 Lipid extract having anti-inflamatory activity
ZA9607626A ZA967626B (en) 1995-09-11 1996-09-10 Lipid extract having anti-inflammatory activity.
US09/029,957 US6083536A (en) 1995-09-11 1996-09-10 Super-critical lipid extract from mussels having anti-inflammatory activity
PCT/AU1996/000564 WO1997009992A1 (en) 1995-09-11 1996-09-10 Lipid extract having anti-inflammatory activity
DK96929129T DK0850068T3 (da) 1995-09-11 1996-09-10 Lipidekstrakt med antiinflammatorisk aktivitet
AU68656/96A AU703368B2 (en) 1995-09-11 1996-09-10 Lipid extract having anti-inflammatory activity
ES96929129T ES2241001T3 (es) 1995-09-11 1996-09-10 Extracto lipidico que tiene actividad antinflamatoria.
PT96929129T PT850068E (pt) 1995-09-11 1996-09-10 Extracto lipidico com actividade anti-inflamatoria
DE69634666T DE69634666T2 (de) 1995-09-11 1996-09-10 Lipid-extrakte mit entzündungshemmender aktivität
JP51149997A JP4101876B2 (ja) 1995-09-11 1996-09-10 抗炎症活性を有する脂質抽出物
EP96929129A EP0850068B1 (en) 1995-09-11 1996-09-10 Lipid extract having anti-inflammatory activity
AT96929129T ATE293984T1 (de) 1995-09-11 1996-09-10 Lipid-extrakte mit entzündungshemmender aktivität
CA002231803A CA2231803C (en) 1995-09-11 1996-09-10 Lipid extract having anti-inflammatory activity
US09/610,484 US6346278B1 (en) 1995-09-11 2000-07-05 Lipid extract having anti-inflammatory activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPN5311A AUPN531195A0 (en) 1995-09-11 1995-09-11 Lipid extract having anti-inflamatory activity

Publications (1)

Publication Number Publication Date
AUPN531195A0 true AUPN531195A0 (en) 1995-10-05

Family

ID=3789640

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPN5311A Abandoned AUPN531195A0 (en) 1995-09-11 1995-09-11 Lipid extract having anti-inflamatory activity

Country Status (12)

Country Link
US (2) US6083536A (enExample)
EP (1) EP0850068B1 (enExample)
JP (1) JP4101876B2 (enExample)
AT (1) ATE293984T1 (enExample)
AU (1) AUPN531195A0 (enExample)
CA (1) CA2231803C (enExample)
DE (1) DE69634666T2 (enExample)
DK (1) DK0850068T3 (enExample)
ES (1) ES2241001T3 (enExample)
PT (1) PT850068E (enExample)
WO (1) WO1997009992A1 (enExample)
ZA (1) ZA967626B (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN531195A0 (en) * 1995-09-11 1995-10-05 J.W. Broadbent Nominees Pty. Ltd. Lipid extract having anti-inflamatory activity
JP2002502311A (ja) 1997-06-04 2002-01-22 セルラー インプルーブメンツ リミテッド 生物材料の破砕のための方法および装置
SE9703085D0 (sv) * 1997-08-27 1997-08-27 Micro Active Protein In Sweden Anti-microbial composition
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
US7220427B2 (en) 1998-07-08 2007-05-22 Oryxe Mixture for transdermal delivery of low and high molecular weight compounds
DE19838794A1 (de) * 1998-08-26 2000-03-09 Aristavet Veterinaerspezialita Zusammensetzung zur Behandlung von Osteoarthritis und zur nutritiven Behandlung des Gelenkknorpels
AUPP910699A0 (en) * 1999-03-10 1999-04-01 Pharmalink International Limited Inhibitor of lipoxygenase pathways
AU2005200953B2 (en) * 1999-03-22 2007-07-12 Mars, Incorporated Pet food for maintenance of joint health and alleviation of arthritic symptoms in companion animals and method of manufacturing same
US6596303B1 (en) * 1999-03-22 2003-07-22 Mars Incorporated Pet food for maintenance of joint health and alleviation of arthritic symptoms in companion animals
US20020018787A1 (en) * 1999-05-21 2002-02-14 Roger V. Kendall Methods and compositions for modulating immune response and for the treatment of inflammatory disease
DE60038320D1 (de) * 1999-07-21 2008-04-24 Bomac Research Ltd Mittel zur bekämpfung von entzündungen und/oder degenerativen erkrankungen
WO2001013956A2 (en) * 1999-08-26 2001-03-01 Ganeden Biotech, Inc. Use of emu oil a carrier for antifungal, antibacterial, and antiviral medications
AUPR030800A0 (en) * 2000-09-22 2000-10-12 Pharmalink International Limited Immunomodulatory preparation
AU9347701A (en) * 2000-09-22 2002-04-02 Pharmalink Internat Ltd Immunomodulatory preparation
US7519546B2 (en) * 2001-04-30 2009-04-14 General Electric Company Maintaining synchronization of information published to multiple subscribers
DK1417211T3 (da) 2001-07-27 2007-10-08 Neptune Technologies & Bioress Naturlige phospholipider af marin oprindelse, der indeholder flavonoider og polyumættede phospholipider, og deres anvendelse
AUPS082102A0 (en) * 2002-03-01 2002-03-21 Women's And Children's Hospital Therapeutic properties of oils
AU2003222002A1 (en) * 2002-03-14 2003-09-29 Jackie H. Mcclung Pharmaceutically active compounds containing phosphorous defficient oil
DE20210182U1 (de) * 2002-07-01 2002-10-02 Bio-Innovation Development Ltd., Christchurch Wirkstoffzusammensetzung aus Bestandteilen der Grünlippenmuschel (perna canaliculus) und zusätzlichen Omega-3-Fettsäuren
JP2006520389A (ja) * 2003-03-14 2006-09-07 フードサイエンス、コーポレイション Ｐｅｒｎａｃａｎａｌｉｃｕｌｕｓ成分およびｐｅｒｎａｃａｎａｌｉｃｕｌｕｓエキスを用いる癌の処置方法
US7052715B2 (en) * 2003-04-11 2006-05-30 All Natural Fmg, Inc. Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof
US7033998B2 (en) * 2003-04-11 2006-04-25 All Natural Fmg, Inc. Alcohol-free transdermal insulin composition and processes for manufacture and use thereof
CA2554932A1 (en) * 2004-01-30 2005-08-11 Bionovate Limited Solvent extraction of lipids such as essential fatty acids
GB0411165D0 (en) * 2004-05-19 2004-06-23 Bionovate Ltd Hyaluronic acid containing pharmaceutical or veterinary compounds
GB0411166D0 (en) * 2004-05-19 2004-06-23 Bionovate Ltd Treatment for asthma and arthritis
US20060039992A1 (en) * 2004-06-02 2006-02-23 Miller Bruce A Jr Novel compositions and methods utilizing green-lipped mussel and fatty acids
WO2006052150A1 (en) * 2004-11-15 2006-05-18 University Of Otago Mussel extract composition with enhanced anti-inflammatory activity
US8092839B2 (en) * 2004-12-13 2012-01-10 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer and other diseases
US8431165B2 (en) * 2004-12-13 2013-04-30 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer and other diseases
NZ563125A (en) * 2005-06-03 2009-11-27 Mcfarlane Marketing Aust Pty L Lipid extract of mussels and method for preparation thereof
NZ547429A (en) * 2006-05-24 2009-09-25 Ind Res Ltd Extraction of highly unsaturated lipids with liquid dimethyl ether
US20090238763A1 (en) * 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
HUE033687T2 (en) 2006-07-18 2017-12-28 Techfields Biochem Co Ltd Ibuprofen positively charged water soluble prodrugs with very fast skin penetration rates
PL2046727T3 (pl) 2006-07-25 2014-08-29 Techfields Biochem Co Ltd Dodatnio naładowane rozpuszczalne w wodzie proleki diklofenaku o bardzo szybkim stopniu przenikania przez skórę
PT2049482E (pt) 2006-08-08 2016-02-24 Techfields Biochem Co Ltd Profármacos solúveis em água carregados positivamente de ácidos aril- e heteroarilacéticos com velocidade de penetração na pele muito rápida
PL2084132T3 (pl) 2006-09-03 2019-03-29 Techfields Biochem Co. Ltd Dodatnio naładowane rozpuszczalne w wodzie proleki z kwasów n-arylantranilowych z bardzo szybką penetracją skóry
EP3388417A1 (en) 2006-09-03 2018-10-17 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate
WO2008035756A1 (en) * 2006-09-22 2008-03-27 Heimat Co., Ltd. Anti-angiogenic composition comprising extract having anti-angiogenic activity and lecithin
CA2665081C (en) * 2006-10-02 2015-12-01 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of prostaglandins and related compounds with very high skin penetration rates
EP2084165B1 (en) 2006-10-11 2013-06-12 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of oxicams and related compounds with very high skin penetration rate
NZ552238A (en) * 2006-12-20 2009-07-31 Seperex Nutritionals Ltd An extract
WO2008146298A1 (en) * 2007-06-01 2008-12-04 Ganga Raju Gokaraju Use of aphanamixis polystacha extracts or fractions against 5 -lipoxygenase mediated diseases
JP2010529101A (ja) * 2007-06-04 2010-08-26 テックフィールズ インコーポレイテッド 非常に速い皮膚及び膜浸透速度を有するｎｓａｉａプロドラッグ及びその新規医薬使用
AU2008355537B2 (en) * 2008-04-28 2014-02-06 21 Holding Sas Di Monico Cav. Silvano Pharmaceutical formulation containing palmitoyl ethanolamide and stearoyl ethanolamide
CN108191846B (zh) 2008-12-04 2021-08-20 于崇曦 高穿透性组合物及其应用
JP5313064B2 (ja) * 2009-07-03 2013-10-09 株式会社ノエビア 中性脂肪蓄積促進剤、豊胸剤
HK1207562A1 (en) 2012-01-18 2016-02-05 苏州泰飞尔医药有限公司 High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions
EP2938324B1 (en) 2012-12-31 2023-11-08 JRX Biotechnology, Inc. Liquid topical pharmaceutical nano-emulsion formulations
JP6176655B2 (ja) * 2013-07-02 2017-08-09 御木本製薬株式会社 マトリックスメタロプロテアーゼ活性阻害剤、皮膚外用剤、老化防止用皮膚外用剤、シワ防止用皮膚外用剤、慢性関節リウマチ及び他の疾患の治療又は予防剤
BR112018000953A2 (pt) * 2015-07-20 2018-09-11 Bengt I. Samuelsson Institute Of Life Science Research produto de proteína adesiva de mexilhão e aplicações do mesmo na supressão de inflamações de pele
EP3349717A4 (en) 2015-09-17 2019-04-17 JRX Biotechnology, Inc. APPROACHES TO IMPROVE SKIN HYDROGENATION OR HUMIDIFICATION
AU2017380470B2 (en) * 2016-12-20 2022-12-22 Sanford Limited Method of processing shellfish and resulting compositions
CN111432654A (zh) * 2017-12-04 2020-07-17 雾凇科技有限公司 从甲壳类捕获物中生产蛋白质磷脂复合物的方法
NZ755776A (en) * 2017-12-22 2020-05-29 Pharmalink International Ltd Lipid combinations
BR112022014320A2 (pt) * 2020-01-21 2022-09-13 Lintbells Ltd Composição, produto alimentar, nutracêutico ou suplemento e método para tratar um indivíduo
US12604918B2 (en) 2020-01-21 2026-04-21 Lintbells Limited Synergistic compositions
CN113041263B (zh) * 2021-03-15 2023-07-25 青岛大学 一种贻贝功能性脂质在制备治疗2型糖尿病产品中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0010061B1 (en) * 1978-09-25 1983-07-13 Stuart John Mc Farlane Pharmaceutical preparations containing a mollusc extract
US4801453A (en) 1984-05-01 1989-01-31 James M. Broadbent Stabilized mussel extract
AUPM740594A0 (en) 1994-08-11 1994-09-01 J.W. Broadbent Nominees Pty. Ltd. Anti-inflammatory preparation
AU3156595A (en) * 1994-08-11 1996-03-07 J.W. Broadbent Nominees Pty. Ltd. Anti-inflammatory preparation
AUPN531195A0 (en) * 1995-09-11 1995-10-05 J.W. Broadbent Nominees Pty. Ltd. Lipid extract having anti-inflamatory activity

Also Published As

Publication number Publication date
JPH11512400A (ja) 1999-10-26
US6083536A (en) 2000-07-04
ATE293984T1 (de) 2005-05-15
CA2231803A1 (en) 1997-03-20
DK0850068T3 (da) 2005-08-15
ES2241001T3 (es) 2005-10-16
EP0850068B1 (en) 2005-04-27
EP0850068A4 (en) 2000-09-13
CA2231803C (en) 2004-11-23
ZA967626B (en) 1997-09-03
JP4101876B2 (ja) 2008-06-18
WO1997009992A1 (en) 1997-03-20
EP0850068A1 (en) 1998-07-01
PT850068E (pt) 2005-08-31
US6346278B1 (en) 2002-02-12
DE69634666D1 (de) 2005-06-02
DE69634666T2 (de) 2006-04-27

Similar Documents

Publication Publication Date Title
ZA967626B (en) Lipid extract having anti-inflammatory activity.
AU697311B2 (en) Combined preparation for the therapy of immunological diseases
AU6586896A (en) Fatty acid treatment
SE9600233D0 (sv) Antibakteriell komposition mot helicobacter
AU6915396A (en) Multiple sclerosis treatment
SG52240A1 (en) The use of cetrorelix and other nona-and decapeptides in the preparation of a medicament for combating aids and for growth stimulation
ZA955327B (en) New pharmaceutical preparation for pain management
PT998287E (pt) Utilizacao de levobupivacaina
GB9408775D0 (en) Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
PT920323E (pt) Nova utilizacao de fosfolipidos de origem animal em terapeutica e/ou dietetica
AU6351996A (en) Use of hyaluronic acid and a nsaid for the manufacture of a medicament for the treatment of mucosal diseases
AU6739787A (en) Colony stimulating factor for the treatment of aids-type diseases
AU3092397A (en) Use of p-aminophenol derivatives for the preparation of pharmaceutical compositions useful in the treatment of neurodegenerative diseases
WO1992019234A3 (en) Method of treating/preventing substance abuse using 1-alkyl-5(substituted oxy)-2-aminotetralins
EP0744176A3 (en) Methods for inhibiting bone loss
AU3401093A (en) Therapeutic agent for threatened abortion
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
ES2110104T3 (es) Procedimiento para la administracion de soluciones de factor de estimulacion de las colonias de granulocitos.
IL110888A0 (en) Pharmaceutical compositions for the treatment of liver diseases comprising a benzothiazepine derivative
JO1917B1 (en) A different method for controlling high levels of bilirubin in the blood in newborns
CA2278223A1 (fr) Derives de la 1,4-dihydropyridine et leur utilisation en therapeutique
UA22223A (uk) Спосіб лікуваhhя захворюваhь оргаhа зору
ECSP951424A (es) Procedimiento para la administracion de azitromicina